JP2022502024A5 - - Google Patents

Info

Publication number
JP2022502024A5
JP2022502024A5 JP2021516406A JP2021516406A JP2022502024A5 JP 2022502024 A5 JP2022502024 A5 JP 2022502024A5 JP 2021516406 A JP2021516406 A JP 2021516406A JP 2021516406 A JP2021516406 A JP 2021516406A JP 2022502024 A5 JP2022502024 A5 JP 2022502024A5
Authority
JP
Japan
Prior art keywords
seq
lcvr
hcvr
sequence
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516406A
Other languages
English (en)
Japanese (ja)
Other versions
JP7796531B2 (ja
JP2022502024A (ja
Filing date
Publication date
Priority claimed from EP18306230.6A external-priority patent/EP3626265A1/en
Application filed filed Critical
Publication of JP2022502024A publication Critical patent/JP2022502024A/ja
Publication of JP2022502024A5 publication Critical patent/JP2022502024A5/ja
Priority to JP2025124669A priority Critical patent/JP2025164963A/ja
Application granted granted Critical
Publication of JP7796531B2 publication Critical patent/JP7796531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516406A 2018-09-21 2019-09-20 抗ヒトcd45rc抗体及びその使用 Active JP7796531B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025124669A JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトcd45rc抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
EP18306230.6 2018-09-21
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025124669A Division JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトcd45rc抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022502024A JP2022502024A (ja) 2022-01-11
JP2022502024A5 true JP2022502024A5 (cg-RX-API-DMAC7.html) 2022-09-29
JP7796531B2 JP7796531B2 (ja) 2026-01-09

Family

ID=63713787

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516406A Active JP7796531B2 (ja) 2018-09-21 2019-09-20 抗ヒトcd45rc抗体及びその使用
JP2025124669A Pending JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトcd45rc抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025124669A Pending JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトcd45rc抗体及びその使用

Country Status (13)

Country Link
US (2) US12168694B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626265A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796531B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210070303A (cg-RX-API-DMAC7.html)
CN (1) CN113164595A (cg-RX-API-DMAC7.html)
AU (1) AU2019343746C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005276A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113562A1 (cg-RX-API-DMAC7.html)
IL (1) IL281608B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003281A (cg-RX-API-DMAC7.html)
NZ (1) NZ774030A (cg-RX-API-DMAC7.html)
SG (1) SG11202102659RA (cg-RX-API-DMAC7.html)
WO (1) WO2020058495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20230147657A1 (en) * 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
PL4401842T3 (pl) * 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
WO2017219995A1 (zh) Lag-3抗体、其抗原结合片段及其医药用途
JP7533897B2 (ja) 融合タンパク質およびその使用
KR20150063447A (ko) 알파-시누클레인을 인식하는 항체
JP7051150B2 (ja) 気分障害の治療及び診断のための抗-配列類似性19を持つファミリー、メンバーa5抗体の用途
JP2018506277A5 (cg-RX-API-DMAC7.html)
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
JP7618240B2 (ja) 脳神経系疾患の予防または治療用組成物
JP2017507131A5 (cg-RX-API-DMAC7.html)
JP2018519804A (ja) 抗Pre−S1 HBV抗体
JP7455749B2 (ja) 頭頸部癌の処置
US20250042980A1 (en) Complement factor h antibodies
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2021098822A1 (zh) 一种双特异性抗体
KR20230084166A (ko) Ox40 관련 질환을 치료하는 방법
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用
JP2022502024A (ja) 抗ヒトcd45rc抗体及びその使用
WO2023286694A1 (ja) 炎症性腸疾患を治療するための医薬組成物
JP2023538518A5 (cg-RX-API-DMAC7.html)
CA3252868A1 (en) COMPOSITIONS AND METHODS FOR THE DEPLOYMENT OF DISEASED HEMATOPOIETIC STEM CELLS
JP2024523514A5 (cg-RX-API-DMAC7.html)
JP2023534779A5 (cg-RX-API-DMAC7.html)
CN115703835B (zh) 一种抗人crr9单克隆抗体及其制备方法和应用
WO2015063228A9 (en) Il-3 blockade in systemic lupus erythematosus and multiple sclerosis